Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    EyePoint Pharmaceuticals ...

    NASDAQ: EYPT · Real-Time Price · USD
    10.06
    -0.31 (-2.99%)
    At close: Jun 27, 2025, 12:09 PM

    EyePoint Pharmaceuticals Statistics

    Share Statistics

    EyePoint Pharmaceuticals has 68.81M shares outstanding. The number of shares has increased by 31.96% in one year.

    Shares Outstanding

    n/a
    		 68.81M

    Shares Change (YoY)

    n/a
    		 31.96%

    Shares Change (QoQ)

    n/a
    		 0.7%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 59.81M

    Failed to Deliver (FTD) Shares

    n/a
    		 3

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 7.17M, so 10.42% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 7.17M

    Short % of Shares Out

    n/a
    		 10.42%

    Short % of Float

    n/a
    		 12.49%

    Short Ratio (days to cover)

    n/a
    		 6.55

    Valuation Ratios

    The PE ratio is -3.2 and the forward PE ratio is -3.6. EyePoint Pharmaceuticals's PEG ratio is -0.12.

    PE Ratio

    n/a
    		 -3.2

    Forward PE

    n/a
    		 -3.6

    PS Ratio

    n/a
    		 9.69

    Forward PS

    n/a
    		 1.3

    PB Ratio

    n/a
    		 1.25

    P/FCF Ratio

    n/a
    		 -3.22

    PEG Ratio

    n/a
    		 -0.12
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for EyePoint Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.81, with a Debt / Equity ratio of 0.06.

    Current Ratio

    n/a
    		 7.81

    Quick Ratio

    n/a
    		 7.77

    Debt / Equity

    n/a
    		 0.06

    Debt / EBITDA

    n/a
    		 -0.17

    Debt / FCF

    n/a
    		 -0.17

    Interest Coverage

    n/a
    		 -10418.14

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $262,260.61

    Profits Per Employee

    n/a
    		 $-793,151.52

    Employee Count

    n/a
    		 165

    Asset Turnover

    n/a
    		 0.1

    Inventory Turnover

    n/a
    		 1.61

    Taxes

    Income Tax

    n/a
    		 90K

    Effective Tax Rate

    n/a
    		 -0.07%

    Stock Price Statistics

    The stock price has increased by 18.97% in the last 52 weeks. The beta is 1.64, so EyePoint Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.64

    52-Week Price Change

    n/a
    		 18.97%

    50-Day Moving Average

    n/a
    		 7.2

    200-Day Moving Average

    n/a
    		 7.8

    Relative Strength Index (RSI)

    n/a
    		 72.76

    Average Volume (20 Days)

    n/a
    		 825,469

    Income Statement

    In the last 12 months, EyePoint Pharmaceuticals had revenue of 43.27M and earned -130.87M in profits. Earnings per share was -2.32.

    Revenue

    n/a
    		 43.27M

    Gross Profit

    n/a
    		 39.56M

    Operating Income

    n/a
    		 -145.85M

    Net Income

    n/a
    		 -130.87M

    EBITDA

    n/a
    		 -129.23M

    EBIT

    n/a
    		 -130.77M

    Earnings Per Share (EPS)

    n/a
    		 -2.32
    Full Income Statement

    Balance Sheet

    The company has 99.7M in cash and 21.86M in debt, giving a net cash position of 77.85M.

    Cash & Cash Equivalents

    n/a
    		 99.7M

    Total Debt

    n/a
    		 21.86M

    Net Cash

    n/a
    		 77.85M

    Retained Earnings

    n/a
    		 -873.02M

    Total Assets

    n/a
    		 362.56M

    Working Capital

    n/a
    		 285.31M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -126.23M and capital expenditures -4.05M, giving a free cash flow of -130.28M.

    Operating Cash Flow

    n/a
    		 -126.23M

    Capital Expenditures

    n/a
    		 -4.05M

    Free Cash Flow

    n/a
    		 -130.28M

    FCF Per Share

    n/a
    		 -2.31
    Full Cash Flow Statement

    Margins

    Gross margin is 91.42%, with operating and profit margins of -337.06% and -302.43%.

    Gross Margin

    n/a
    		 91.42%

    Operating Margin

    n/a
    		 -337.06%

    Pretax Margin

    n/a
    		 -302.22%

    Profit Margin

    n/a
    		 -302.43%

    EBITDA Margin

    n/a
    		 -298.63%

    EBIT Margin

    n/a
    		 -337.06%

    FCF Margin

    n/a
    		 -301.06%

    Dividends & Yields

    EYPT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for EYPT is $26.5, which is 154.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $26.5

    Price Target Difference

    n/a
    		 154.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Dec 9, 2020. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Dec 9, 2020

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 0.68

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist